Vernalis And Servier Join Forces To Develop Oncology Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Servier was attracted to Vernalis based on the firm’s development work with Novartis on another oncology compound, Vernalis CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Sanofi’s Zimulti Goes To Advisory Committee
FDA’s Endocrinologic & Metabolic Drugs Advisory Committee will review the obesity agent, formerly known as Acomplia, June 13.
Endo, Vernalis Seek First Triptan Menstrual Migraine Indication With Frova sNDA
Frovatriptan sNDA is supported by data from four studies, including two Phase III trials evaluating efficacy in short-term prevention of MM.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee